58.2 F
Laguna Hills
Friday, Dec 9, 2022
-Advertisement-

Allergan Buys Eye Therapy Developer

Allergan Plc bought RetroSense Therapeutics for $60 million and milestone payments.

Allergan maintains a hub in Irvine for eyecare and aesthetics medicine product lines; its U.S. operations are in New Jersey and its corporate headquarters is in Ireland. It bought a glaucoma-treatment device developer in Menlo Park last month for $95 million plus milestones.

RetroSense in Ann Arbor, Mich., is developing a gene therapy to treat retinitis pigmentosa, with a follow-on indication for dry age-related macular degeneration.

The gene therapy is currently known as RST-001 and is the company’s lead candidate for future approval. It’s in pre-clinical stage and working toward human clinical trials.

Retinitis Pigmentosa is an inherited condition that produces gradual loss of vision from retinal degradation; dry age-related macular degeneration produces loss in the center of the field of vision as the retina’s center deteriorates.

RST-001 uses a photosensitivity gene to make new photosensors in retinal cells and restore vision.

It isn’t known whether Allergan would move RetroSense operations to Irvine.

Want more from the best local business newspaper in the country?

Sign-up for our FREE Daily eNews update to get the latest Orange County news delivered right to your inbox!

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-